A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M09D1 for Injection in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
Latest Information Update: 18 Jul 2025
At a glance
- Drugs BL M09D1 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 18 Jul 2025 New trial record